Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents

被引：43

作者：

Verrotti, Alberto ^{[2
]}

Cerminara, Caterina ^{[1
]}

Coppola, Giangennaro ^{[3
]}

Franzoni, Emilio ^{[4
]}

Parisi, Pasquale

Iannetti, Paola ^{[5
]}

Aloisi, Paolo ^{[6
]}

Tozzi, Elisabetta ^{[6
]}

Cusmai, Raffaella

Vigevano, Federico

Chiarelli, Francesco ^{[2
]}

Curatolo, Paolo ^{[1
]}

机构：

[1] Univ Roma Tor Vergata, Rome, Italy

[2] Univ G dAnnunzio, Dept Paediat, Chieti, Italy

[3] Univ Naples Federico II, Dept Child Neurol & Psychiat, I-80138 Naples, Italy

[4] Univ Bologna, Dept Child Neurol & Psychiat, I-40126 Bologna, Italy

[5] Univ Rome, Dept Paediat, Rome, Italy

[6] Univ Aquila, Neurophysiol Unit, Dept Paediat, I-67100 Laquila, Italy

来源：

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY | 2008年 / 50卷 / 01期

关键词：

D O I：

10.1111/j.1469-8749.2007.02009.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in juvenile myoclonic epilepsy (JME). The study group consisted of 32 patients with epilepsy (20 males, 12 females) with a mean age of 13 years 3 months (SD 7y 11mo) at seizure onset. LEV was administered as the first drug; all patients were followed up at 6 and 12 months. The dose that achieved seizure control ranged from 1000 to 2500mg/daily. At 6-month evaluation: 15 patients were seizure free; 14 patients were responders (> 50% reduction in seizures); and three patients had marginal effects (< 50% reduction of seizures). At 12-month evaluation: 29 patients were seizure free; three patients were responders. No patients reported adverse events. These data provide preliminary evidence that LEV may be effective for treating patients with newly diagnosed JME.

引用

页码：29 / 32

页数：4

共 27 条

[1]

Andermann E, 2006, EPILEPSIA, V47, P187

[2] PROPOSAL FOR REVISED CLASSIFICATION OF EPILEPSIES AND EPILEPTIC SYNDROMES [J].